ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Infliximab (including biosimilars): Drug information

Infliximab (including biosimilars): Drug information
(For additional information see "Infliximab (including biosimilars): Patient drug information" and see "Infliximab (including biosimilars): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Serious infections:

Patients treated with infliximab are at an increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.

Discontinue infliximab if a patient develops a serious infection or sepsis.

Reported infections include the following:

Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab use and during therapy. Treatment for latent infection should be initiated prior to infliximab use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk of invasive fungal infections who develop severe systemic illness.

Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with infliximab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with infliximab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Malignancy:

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab.

Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of reported infliximab cases have occurred in patients with Crohn disease or ulcerative colitis, and most were in adolescent and young adult males.

Brand Names: US
  • Avsola;
  • Inflectra;
  • Remicade;
  • Renflexis
Brand Names: Canada
  • Avsola;
  • Inflectra;
  • Remicade;
  • Remsima SC;
  • Renflexis
Pharmacologic Category
  • Antirheumatic, Disease Modifying;
  • Gastrointestinal Agent, Miscellaneous;
  • Immunosuppressant Agent;
  • Monoclonal Antibody;
  • Tumor Necrosis Factor (TNF) Blocking Agent
Dosing: Adult

Dosage guidance:

Dosage form information: Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), and Renflexis (infliximab-abda) are approved as biosimilars to Remicade (infliximab). In Canada, Avsola, Inflectra, and Renflexis are also approved as biosimilars to Remicade (infliximab).

Clinical considerations: Premedication with antihistamines (H1-antagonist +/- H2-antagonist), acetaminophen, and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions.

Ankylosing spondylitis

Ankylosing spondylitis: IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 weeks thereafter.

Colitis, immune checkpoint inhibitor-induced

Colitis, immune checkpoint inhibitor-induced (off-label use):

Note: For grade 2, 3, or 4 colitis with either high-risk endoscopic features on initial endoscopy examination or with persistent symptoms despite 3 days of corticosteroid therapy, consider adding infliximab to the treatment regimen (Ref).

IV: 5 mg/kg at week 0, a second dose may be repeated 2 weeks later, and a third dose may be considered at 6 weeks if needed; use in combination with a corticosteroid (Ref).

COVID-19, hospitalized patients

COVID-19, hospitalized patients (alternative agent) (off-label use):

Note: For use in patients who are hospitalized who require oxygen (eg, high-flow oxygen, noninvasive ventilation) and those with lower but increasing oxygen requirements and evidence of systemic inflammation who cannot use preferred agents (Ref).

IV: 5 mg/kg as a single dose as part of an appropriate combination regimen (Ref).

Crohn disease, moderate to severe, induction and maintenance of remission

Crohn disease, moderate to severe, induction and maintenance of remission: Note: Combination with an immunomodulator (ie, thiopurine or methotrexate) is generally preferred (Ref).

IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; dose may be increased to 10 mg/kg every 8 weeks in patients who respond but then lose their response. If no response by week 14, consider discontinuing therapy.

Plaque psoriasis

Plaque psoriasis: IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. Note: Some patients may require 10 mg/kg and/or dosing as frequently as every 4 weeks during the maintenance phase (Ref).

Psoriatic arthritis

Psoriatic arthritis (with or without methotrexate): IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.

Pustular psoriasis

Pustular psoriasis (off-label use): IV: 5 mg/kg at week 0, 2, and 6, followed by 5 mg/kg every 8 weeks for up to 46 weeks (Ref).

Rheumatoid arthritis

Rheumatoid arthritis: Note: For use as adjunctive therapy in patients who have not met treatment goals despite maximally tolerated methotrexate therapy; may also be used off label as an alternative to methotrexate in disease-modifying antirheumatic drug–naive patients with moderate to high disease activity (Ref).

IV:

Induction therapy followed by IV maintenance therapy: 3 mg/kg at 0, 2, and 6 weeks.

Induction therapy followed by SUBQ (Remsima [Canadian product]) maintenance therapy: 3 mg/kg at 0 and 2 weeks.

Maintenance therapy: 3 mg/kg every 8 weeks thereafter; for patients who have incomplete responses, consider adjusting the dose up to 10 mg/kg every 8 weeks or treating as often as every 4 weeks, although consider the risk of serious infections is increased at higher doses or with more frequent administration.

SUBQ: Remsima (Canadian product):

Induction therapy: 120 mg at 0, 1, 2, 3, and 4 weeks.

Initial maintenance therapy: 120 mg once every 2 weeks; begin 2 weeks following the week 4 SUBQ dose or 4 weeks following the week 2 IV dose.

Patients receiving IV maintenance therapy and switching to SUBQ maintenance therapy: 120 mg once every 2 weeks; administer first dose 8 weeks after the last IV infusion.

Missed doses:

≤7 days: Administer missed dose immediately; administer following dose as per originally planned date and thereafter on the original biweekly schedule.

≥8 days: Skip the missed dose and administer next dose as per the originally planned date and thereafter on the original biweekly schedule.

Sarcoidosis, refractory

Sarcoidosis, refractory (adjunctive agent) (off-label use): Note: For use as adjunctive therapy in patients in whom treatment goals have not been met despite glucocorticoids and other immunosuppressant therapy (eg, methotrexate); use in combination with glucocorticoids and/or methotrexate may prevent infliximab autoantibody formation (Ref).

Initial: IV: 3 to 5 mg/kg at weeks 0, 2, and 6 (Ref).

Maintenance: IV: 3 to 5 mg/kg every 4 to 8 weeks thereafter (Ref). The optimal frequency and duration of therapy are not known, and must be individualized based on response; after a stable response is achieved (eg, after ≥6 to 12 months of therapy), may consider gradually prolonging the dosing interval (eg, up to every 12 weeks) or reducing the dose and discontinue if response remains adequate after although approaches vary (Ref).

Ulcerative colitis

Ulcerative colitis: IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. Doses up to 10 mg/kg were studied in clinical trials with similar efficacy observed with both doses (Ref); combination therapy with a thiopurine (eg, azathioprine, mercaptopurine) has shown increased efficacy (Ref).

Dosage adjustment with heart failure: Weigh risk versus benefits for individual patient:

Mild heart failure (NYHA class I/II): No dosage adjustment necessary; use with caution and monitor closely for worsening of heart failure.

Moderate to severe (NYHA class III or IV): ≤5 mg/kg.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.

Note: Abnormal baseline liver chemistries (AST/ALT) are common in patients with autoimmune disorders and often improve with infliximab use; however, baseline LFT elevations should be investigated to ensure etiology (eg, viral hepatitis, metabolic dysfunction associated steatotic liver disease [MASLD]) has been determined and mitigated prior to initiation of infliximab treatment (Ref). Consider holding infliximab prior to living donor solid organ transplant (eg, hold IV infliximab for at least 4 weeks; hold SUBQ infliximab for 1 week) (Ref).

Initial or dose titration with preexisting liver cirrhosis: No dosage adjustment necessary for any degree of liver dysfunction (Ref).

Elevated liver-associated enzymes during treatment:

Infliximab-induced hepatoxicity: Note: Idiosyncratic elevation of hepatic transaminases occur in >30% of patients at around 10 weeks; especially in those with elevated ALT at baseline or MASLD (Ref).

AST/ALT <5 times ULN: Continue infliximab therapy with frequent (eg, every 2 weeks) LFT monitoring; most cases (~75%) resolve without further intervention (Ref).

AST/ALT ≥5 times ULN: Discontinue infliximab therapy and consult hepatologist (Ref). May be indicative of infliximab-induced autoimmune hepatitis, which may cause severe liver injury and can be fatal or lead to liver transplantation.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Infliximab (including biosimilars): Pediatric drug information")

Dosage guidance:

Clinical considerations: The manufacturer recommends to consider premedication with antihistamines (H1-antagonist and/or H2-antagonist), acetaminophen, and/or corticosteroids to prevent and/or manage infusion-related reactions; however, efficacy of routine premedication is uncertain (Ref).

Crohn disease

Crohn disease:

Note: Guidelines recommend anti-tumor necrosis factor (TNF) agent use for maintenance and remission in patients with new-onset Crohn disease with high risk for complicated disease course, or in patients with active Crohn disease who do not achieve or maintain remission with an immunomodulator (Ref).

Children ≥3 years and Adolescents: Limited data available in ages 3 to <6 years: IV: Initial: 5 mg/kg/dose at 0, 2, and 6 weeks, followed by maintenance: 5 mg/kg/dose every 8 weeks thereafter. Note: Therapeutic drug monitoring and dose adjustment as necessary are recommended. Patients weighing <30 kg, those with extensive disease, or those with low albumin may need higher dosing (eg, 10 mg/kg/dose) and/or shorter intervals (eg, every 4 to 6 weeks) (Ref).

Juvenile idiopathic arthritis; refractory to conventional disease-modifying drugs

Juvenile idiopathic arthritis; refractory to conventional disease-modifying drugs: Limited data available:

Children ≥4 years and Adolescents: IV: Initial: 5 to 10 mg/kg at 0, 2, and 6 weeks; then 5 to 10 mg/kg/dose every 4 to 8 weeks thereafter, in combination with methotrexate during induction and maintenance. A wide range of doses have been reported, including doses as low as 3 mg/kg/dose and a target dose as high as 10 to 20 mg/kg/dose (Ref).

Kawasaki disease, refractory to IVIG

Kawasaki disease, refractory to IVIG: Limited data available: Infants and Children: IV: 5 to 10 mg/kg/dose as a single infusion (Ref).

Multisystem inflammatory syndrome in children associated with SARS-CoV-2

Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2: Very limited data available: Note: Recommended for intensification therapy in patients who do not improve within 24 hours of initial MIS-C therapy (ie, immune globulin and methylprednisolone); do not use in patients with features of macrophage activation syndrome or in combination with anakinra (Ref).

Infants, Children, and Adolescents: IV: 5 to 10 mg/kg as a single infusion (Ref).

Ulcerative colitis

Ulcerative colitis:

Note: Guidelines recommend use for chronically active or steroid-dependent ulcerative colitis uncontrolled by other agents (Ref).

Children ≥6 years and Adolescents: IV: Initial: 5 mg/kg/dose at 0, 2, and 6 weeks, followed by maintenance: 5 mg/kg/dose every 8 weeks thereafter. Note: Therapeutic drug monitoring and dose adjustment as appropriate are recommended. Patients with low body weight (eg, <30 kg), high BMI, high inflammatory burden, or low albumin may need higher dosing (eg, 10 mg/kg/dose) or shorter intervals (eg, every 4 weeks) (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Pediatric

Hepatic impairment prior to treatment initiation: There are no dosage adjustments provided in the manufacturer's labeling.

Hepatotoxicity during treatment: Jaundice and/or marked increase in liver enzymes (≥5 times ULN): Discontinue treatment.

Adverse Reactions (Significant): Considerations
Autoimmune disorder

Autoantibody development may occur with the use of tumor necrosis factor (TNF) alpha inhibitors, including infliximab. Most frequently, autoantibodies include anti-nuclear antibody, anti–double-stranded DNA; less frequently, anti-extractable nuclear antigen, anti-histone Ab, and anti-cardiolipin Ab (Ref). Frequency of autoantibody development varies depending on underlying disease, specific TNF alpha inhibitor medication, and the duration of use; the clinical significance of asymptomatic antibody positivity is unclear (Ref). Antibody positivity may rarely result in the development of an autoimmune disorder, such as lupus-like syndrome (Ref). Symptoms include arthralgia, myalgia, mucocutaneous symptoms (eg, skin rash), cytopenia, fatigue, fever, serositis, and kidney injury (Ref). Development of an autoimmune disorder is associated with a poor treatment response of the original disease to TNF alpha inhibitor therapy (Ref). It is unclear if the development of an autoimmune disorder is a true TNF alpha inhibitor class effect; several reports of rechallenge with the same TNF alpha inhibitor or a different TNF alpha inhibitor after treatment of the initial autoimmune disorder did not result in a recurrence (Ref).

Mechanism: Unknown; postulated mechanisms include bystander activation of autoreactive lymphocytes due to drug-specific immunity, nonspecific activation of lymphocytes, direct cytotoxicity with release of autoantigens, and disruption of central T-cell tolerance (Ref).

Onset: Varied; onset of symptoms ranged from 5 weeks to 2 years post treatment (data with adalimumab) (Ref).

Risk factors:

• Longer disease duration (Ref)

• Females (Ref)

• Ulcerative colitis (Ref)

Demyelinating disease

New-onset or exacerbation of central and peripheral nervous system demyelinating disease, such as multiple sclerosis, optic neuritis, acute transverse myelitis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy, may occur with tumor necrosis factor (TNF) alpha inhibitor, although causality is yet to be proven (Ref). Symptomatic CNS demyelination associated with TNF alpha inhibitors may be monophasic and/or clinically isolated (Ref). Partial or complete resolution may occur after discontinuation of TNF alpha inhibitors (Ref); however, approximately one-third of TNF alpha inhibitor-associated demyelinating episodes evolve into clinically definite multiple sclerosis (Ref).

Mechanism: Unknown; several mechanisms have been postulated, including the following: May trigger CNS demyelination directly by immune activation in genetically and/or immunologically predisposed individuals (Ref); may inhibit remyelination via TNF type-2 receptor (TNFR2) (Ref); may increase ingress of auto-reactive T cells in the CNS; may alter downstream cytokine responses; may neutralize TNF systemically but not within the CNS, creating an artificially high local concentration of brain TNF (known as sponge effect); may permit latent CNS viral infection; or may promote anti-drug antibodies and immune complexes that are contributory to demyelination events (Ref).

Onset: Varied; mean time of exposure to TNF alpha inhibitors before onset of symptoms: 18 months; reported with infliximab after 1 dose and up to 14 years after initiation (Ref).

Risk factors:

• Preexisting or recent onset central or peripheral nervous system demyelinating disorders

Dermatologic reactions

Various cutaneous eruptions have been reported, including psoriasiform eruption (either new onset or exacerbation), hidradenitis suppurativa, lupus-like syndrome, eczematous rash, pustular rash, maculopapular rash, and hypersensitivity angiitis (Ref). In most patients with psoriatic lesions, infliximab can be continued (Ref).

Mechanism: Psoriasiform eruptions: Non–dose-related; possibly related to cytokine imbalance or imbalance between tumor necrosis factor (TNF) alpha and interferon-alpha (Ref).

Onset: Psoriasiform eruptions: Delayed; mean 15.6 ± 10.7 months (Ref).

Risk factors:

• Adult females (psoriatic lesions) (Ref)

• Smoking (psoriatic lesions) (Ref)

• Males (palmoplantar pustulosis)

• Younger patients (<40 years) (palmoplantar pustulosis) (Ref)

• Patients with inflammatory bowel disease compared to other inflammatory diseases (psoriasiform reactions more frequent and severe) (Ref)

• Females (hidradenitis suppurativa) (Ref)

• Cross-reactivity data among TNF alpha inhibitors in patients who develop psoriatic lesions are conflicting (Ref)

Heart failure

New-onset heart failure (HF) and worsening of heart failure have been reported with tumor necrosis factor (TNF) alpha inhibitors, including infliximab; however, data are conflicting, and risk is unclear (Ref). Rheumatoid arthritis (RA) may be a risk factor for HF development (Ref). Some data suggest that TNF alpha inhibitors may reduce the risk of HF in the RA population by improving inflammation, lowering disease activity, and improving surrogate markers of cardiovascular disease (Ref).

Mechanism: Dose-related, not clearly established; postulated mechanisms include pro-inflammatory cytokine activation, accelerated atherosclerosis, and reduced physical activity related to the underlying rheumatologic disease (Ref). “Reverse-signaling” may occur, leading to cardiotoxic effects; TNF on cardiomyocytes of the failing heart may act as receptors, activating intracellular signaling pathways, potentiating the toxic effect of the cytokine (Ref).

Onset: Varied; median 8.5 months (range: 5 to 17 months) (Ref).

Risk factors:

• Higher doses (Ref)

• Preexisting left ventricular dysfunction or HF

• Higher disease activity (inflammation) (eg, disease activity score [DAS28], C-reactive protein, erythrocyte sedimentation rate) (Ref)

Hepatitis B virus reactivation

Reactivation of hepatitis B virus (HBV) may occur with immunosuppressive or biologic therapy, including tumor necrosis factor (TNF) alpha inhibitors (Ref). Reactivation of HBV may occur in both patients who are HBsAg-positive and in patients who are HBsAg-negative/HBcAb-positive with detectable HBV DNA (Ref). Criteria for HBV reactivation includes (1) a rise in HBV DNA compared to baseline (or an absolute level of HBV DNA when a baseline is unavailable) and (2) reverse seroconversion (seroreversion) from HBsAg-negative to HBsAg-positive for patients who are HBsAg-negative and anti-HBc–positive (Ref).

Mechanism: Inhibits stimulation of HBV-specific T lymphocytes, promoting HBV reactivation (Ref).

Onset: Varied; 2 weeks after initiation, up to a year after discontinuation (Ref).

Risk factors:

• Males (Ref)

• Older age (Ref)

• Presence of cirrhosis (Ref)

• High baseline HBV DNA level (Ref)

• HBeAg or HBsAg seropositivity (Ref)

• Absence of anti-HBs among patients with resolved HBV infection (Ref)

• Chronic HBV (Ref)

• Non-A HBV genotype (Ref)

• Hepatitis C, hepatitis D, or HIV co-infection (Ref)

Hepatoxicity

Infliximab has been associated with increased serum transaminases and hepatotoxicity (Ref). Acute hepatic failure, cholestatic hepatitis (including vanishing bile duct syndrome), reactivation of hepatitis B (HBV), and autoimmune hepatitis have been reported (Ref). Elevated aminotransferases between 2 to 3 times the upper limit of normal may occur that are usually transient and asymptomatic (Ref); although, may not always improve after discontinuation of infliximab (Ref). Resolution of symptoms in patients who develop an autoimmune hepatitis may require initiation of corticosteroid therapy (Ref). Immunomodulatory use, in particular methotrexate, may decrease the risk of hepatotoxicity associated with tumor necrosis factor (TNF) alpha inhibitors (Ref). Patients often tolerate a different TNF alpha inhibitor (Ref); although, hepatotoxicity may recur with an alternative agent in some cases (Ref). Hepatotoxicity is more commonly associated with infliximab, compared to adalimumab and other TNF alpha inhibitors (Ref).

Mechanism: Unknown; idiosyncratic drug reaction (Ref) or autoimmunity due to development of autoantibodies (Ref). A hepatocellular pattern of injury is often observed along with induction of antiantibodies (Ref).

Onset: Varied; elevated aminotransferases usually occur after 2 to 5 infusions (Ref). Duration of therapy prior to hepatotoxicity ranges from 3 days to more than 1 year (Ref), with a median duration of approximately 3 months (Ref). Autoimmune hepatitis has a longer latency period than nonimmune cases (16 weeks vs 10 weeks, respectively) (Ref).

Risk factors:

• Abnormal baseline liver biochemistry (Ref)

• Preexisting liver disease (Ref)

• Male sex (Ref)

Infection

Tumor necrosis factor (TNF) alpha inhibitors may be associated with infection (including serious infection). In clinical trials, serious infections were numerically higher among patients treated with TNF alpha inhibitors than among patients who received placebo. Meta-analyses and observational studies have reported inconsistency in risk. One study reported an increase in serious infection in patients treated with TNF alpha inhibitors (Ref). Another study found no increase in risk (Ref). An observational study did not demonstrate an increased infection risk among patients receiving TNF alpha inhibitor versus comparators (Ref). Infections may present as disseminated (rather than local) disease. Tuberculosis disease (including reactivation of tuberculosis infection), invasive fungal infection (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis), and bacterial infection, viral infection, or other opportunistic infection (including legionellosis and listeriosis) have been reported.

One study reported an increased infection risk in patients receiving infliximab compared to other TNF alpha inhibitors (Ref). Another study reported a significantly increased risk of serious infection with infliximab compared with etanercept and adalimumab (Ref). Higher infection risk with infliximab was also observed in several other studies (Ref). A meta-analysis of observational studies in the inflammatory bowel disease population reported that infliximab-based therapy was associated with a lower risk of serious infections compared with adalimumab-based therapy in patients with ulcerative colitis but not Crohn disease (Ref).

Mechanism: Dose-related; TNF alpha is important in the immune response against infections, suggesting that medications that inhibit TNF alpha may increase the risk of infections (Ref). Increased risk with infliximab may be related to large induction doses routinely given in the first 6 weeks of therapy and possibly more complex biologic mechanisms, such as the ability to bind transmembrane TNF (Ref).

Risk factors:

• Higher doses (Ref)

• Older age (Ref)

• Chronic lung or kidney disease (Ref)

• Concurrent immunosuppressants (eg, corticosteroids, methotrexate) (Ref)

• History of an opportunistic infection

• Chronic or recurrent infection

• Conditions that predispose to infections (eg, advanced or poorly controlled diabetes)

• Residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis)

Infusion-related reactions

Infliximab is associated with a variety of hypersensitivity reactions, including immediate (eg, infusion-related reactions) and delayed (eg, serum sickness-like reaction [SSLR], maculopapular rash) reactions in adult and pediatric patients (Ref). Immediate infusion reactions include pruritus, flushing, dyspnea, chest discomfort, hypertension, myalgia, nausea, urticaria, headache, skin rash, and dizziness (Ref). Cardiovascular and cerebrovascular reactions, as well as temporary vision loss, have been reported during and following infusion (Ref). Concurrent immunomodulators (eg, thiopurine, methotrexate) may reduce the risk of immediate infusion reactions (Ref). Cross-reactivity between tumor necrosis factor alpha inhibitors is not well described. Adalimumab has been tolerated in patients with previous infusion reactions following infliximab (Ref). In contrast, there are reports of immediate hypersensitivity reactions with adalimumab in patients who had previous infliximab-related reactions (Ref).

Mechanism: Immediate infusion reactions: Unknown; possibly related to release of cytokines, complement activation, degranulation of mast cells and basophils, or IgE or IgG mediated (Ref). Delayed hypersensitivity reactions: Non–dose-related, immunologic; delayed hypersensitivity reactions including maculopapular eruptions are T-cell mediated (Ref). Serum sickness-like reactions: Non–dose-related, non-immunologic or immunologic; activation of complement resulting in local and systemic inflammatory responses (Ref).

Onset: Immediate infusion reactions: Rapid; during the infusion or within 1 to 2 hours of completion (Ref). Infusion reactions occur most commonly during the third and fourth infusion (Ref); although may occur with the first infusion (Ref). Delayed infusion reactions: Varied; develop >24 hours post infusion, with a mean of 7.2 days (Ref). Serum sickness-like reaction: Varied; develops 1 to 3 weeks following initiation; in patients who have been previously sensitized, reactions can occur as early as 24 to 36 hours following infusion (Ref).

Risk factors:

• Development of antibodies to infliximab increases the risk for acute infusion reactions but not delayed reactions (Ref)

• Episodic administration and resumption of infliximab infusions after a prolonged drug-free interval (>12 weeks) increases risk of late infusion reactions to infliximab (Ref)

• Females, immunosuppressive use for <4 months, and prior infusion reactions are risk factors for subsequent infusion reactions in children (Ref)

Malignancy

Lymphoma and other malignancies (may be fatal) have been reported in children and adolescents receiving tumor necrosis factor (TNF) alpha inhibitors, including infliximab. Half the cases are lymphomas (Hodgkin lymphoma and non-Hodgkin lymphoma), while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants. Hepatosplenic T-cell lymphoma, a rare T-cell lymphoma, has been reported (some fatal) primarily in patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males. Malignant melanoma and Merkel cell carcinoma have been reported. Females with rheumatoid arthritis (RA) had a higher incidence of invasive cervical cancer.

Long-term observational studies and meta-analyses indicate no association between TNF alpha inhibitor therapy and an overall increased risk of cancer (Ref). One study reported a significant increase in lymphomas in patients with RA receiving TNF alpha inhibitors compared to the general population. However, there was no significant increased risk of lymphomas in patients receiving TNF alpha inhibitors compared to those receiving conventional synthetic DMARDs or with dose, increasing time since initiation, or cumulative duration (Ref). Another study reported no difference in the risk of solid tumors in patients with RA receiving TNF alpha inhibitors compared to those receiving conventional synthetic DMARDs (Ref). Other studies reported no increased risk of malignancy recurrence in patients receiving TNF alpha inhibitors (Ref). There was no statistically significant difference in lymphoma with infliximab compared to other TNF alpha inhibitors, and cancer-related mortality was comparable to adalimumab and etanercept (Ref).

Mechanism: May contribute to pro-tumor activity and suppress the anti-tumor response (Ref).

Onset: Delayed; median 30 months (range: 1 to 84 months).

Risk factors:

• History of COPD

• Older age (Ref)

• Psoriasis patients with a history of phototherapy (nonmelanoma skin cancers)

Tuberculosis

Adult and pediatric patients treated with tumor necrosis factor (TNF) alpha inhibitors are at risk for developing tuberculosis (TB) disease (including reactivated tuberculosis) (Ref). A meta-analysis of randomized controlled trials (RCTs) of TNF alpha inhibitors vs control and registry/longitudinal cohort studies of TNF alpha inhibitors vs other DMARDs found a significant increase in TB risk in patients with rheumatoid arthritis (RA) treated with a TNF alpha inhibitor. In the non-RCTs, incidence rates with infliximab were higher than etanercept. Preventive treatment for TB infection reduced TB risk (Ref). In the RCTs, no difference in TB rates were found; however, the failure to detect a difference in TB rates between the two groups may be due to a short observational period (Ref).

Mechanism: TNF alpha inhibitors interfere with TNF alpha induction of the granuloma, which is a crucial defense mechanism in controlling TB (Ref). TNF alpha inhibitors modulate T-cell number, function, and cytokine signaling, important for the control of TB infection (Ref).

Onset: Varied; median 3 to ~40 months (Ref).

Risk factors:

• Residence in an area with high TB prevalence (Ref)

• Known TB exposure or ongoing risk factors for TB exposure (eg, travel to areas with high TB prevalence; residence in correctional facilities, long-term care facilities, or homeless shelters; certain healthcare workers) (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and pediatric patients.

>10%:

Gastrointestinal: Abdominal pain (12% to 26%), nausea (21%)

Hematologic & oncologic: Anemia (≤11%)

Hepatic: Increased serum alanine aminotransferase (<3 × ULN: 17% to 51%; ≥3 × ULN: 2% to 10%; ≥5 × ULN: 1% to 4%)

Hypersensitivity: Infusion-related reaction (≤20%; severe infusion-related reaction: ≤4%) (table 1)

Immunologic: Antibody development (10% to 52%), positive ANA titer (~50%)

Infection: Abscess (≤15%), infection (27% to 74%; including serious infection) (table 2)

Infliximab: Adverse Reaction: Infection

Drug (Infliximab)

Placebo

Population

Dose

Indication

Number of Patients (Infliximab)

Comments

56%

N/A

Children and adolescents

5 mg/kg every 8 or 12 weeks

Crohn disease

112

N/A

59%

N/A

Children and adolescents

5 mg/kg every 8-week infusion

Ulcerative colitis

22

Maintenance therapy

52%

N/A

Children and adolescents

5 mg/kg every 8-week infusion

Ulcerative colitis

60

N/A

74%

N/A

Children and adolescents

5 mg/kg every 8-week infusion

Crohn disease

52

N/A

38%

N/A

Children and adolescents

5 mg/kg every 12-week infusion

Crohn disease

51

N/A

50%

N/A

Adults

5 mg/kg or 10 mg/kg every 8 weeks

Crohn disease

545

Maintenance therapy

27%

18%

N/A

N/A

Ulcerative colitis

N/A

Pooled clinical data

36%

25%

N/A

N/A

N/A

N/A

Pooled clinical data

Nervous system: Headache (18%)

Respiratory: Cough (12%), pharyngitis (8% to 12%), sinusitis (14%), upper respiratory tract infection (12% to 32%)

1% to 10%:

Cardiovascular: Bradycardia, edema, flushing (9%), hypertension (7%) (table 3), hypotension, thrombophlebitis

Infliximab: Adverse Reaction: Hypertension

Drug (Infliximab)

Placebo

Population

Indication

Number of Patients (Infliximab)

Number of Patients (Placebo)

7%

5%

Adults

Rheumatoid arthritis

1,129

350

Dermatologic: Cellulitis, diaphoresis, pruritus (7%) (table 4), skin rash (10%) (table 5)

Infliximab: Adverse Reaction: Pruritus

Drug (Infliximab)

Placebo

Population

Indication

Number of Patients (Infliximab)

Number of Patients (Placebo)

7%

2%

Adults

Rheumatoid arthritis

1,129

350

Infliximab: Adverse Reaction: Skin Rash

Drug (Infliximab)

Placebo

Population

Indication

Number of Patients (Infliximab)

Number of Patients (Placebo)

10%

5%

Adults

Rheumatoid arthritis

1,129

350

Endocrine & metabolic: Dehydration

Gastrointestinal: Constipation, dyspepsia (10%), intestinal obstruction

Genitourinary: Urinary tract infection (8%)

Hematologic & oncologic: Hemolytic anemia, leukopenia (≤9%;), lymphadenopathy, malignant lymphoma, neutropenia (7%), pancytopenia, thrombocytopenia

Hepatic: Hepatitis

Hypersensitivity: Hypersensitivity reaction (≤6%), serum sickness (≤1%), type IV hypersensitivity reaction (1%)

Immunologic: Sarcoidosis

Infection: Bacterial infection (6%), candidiasis (5%), sepsis, viral infection (8%)

Nervous system: Dizziness, fatigue (9%), pain (8%)

Neuromuscular & skeletal: Arthralgia (8%) (table 6), bone fracture (7%)

Infliximab: Adverse Reaction: Arthralgia

Drug (Infliximab)

Placebo

Population

Indication

Number of Patients (Infliximab)

Number of Patients (Placebo)

8%

7%

Adults

Rheumatoid arthritis

1,129

350

Respiratory: Bronchitis (10%), lower respiratory tract infection, pleurisy, pneumonia (≤2%), pulmonary edema

Miscellaneous: Fever (7%)

<1%:

Hypersensitivity: Anaphylaxis

Infection: Coccidioidomycosis, cytomegalovirus disease, herpes zoster infection, histoplasmosis, nocardiosis, opportunistic infection

Nervous system: Seizure

Respiratory: Infection due to an organism in genus Pneumocystosis, tuberculosis (including reactivated tuberculosis)

Frequency not defined: Dermatologic: Dermal ulcer

Postmarketing:

Cardiovascular: Acute myocardial infarction, cardiac arrhythmia, chest discomfort (Lichtenstein 2015), heart failure (Chung 2003), ischemic heart disease, pericardial effusion, vasculitis (systemic and cutaneous), worsening of heart failure (Chung 2003)

Dermatologic: Acneiform eruption (Senila 2017), acute generalized exanthematous pustulosis (including acute localized exanthematous pustulosis) (Meiss 2007, Senila 2017), bullous dermatitis (linear IgA) (Bryant 2016), eczematous rash (Moustou 2009), erythema multiforme, lichenoid eruption (Moustou 2009), maculopapular rash (Gamarra 2006), malignant melanoma, Merkel cell carcinoma, psoriasiform eruption (Hawryluk 2012), psoriasis (including exacerbation, new onset, palmoplantar, or pustular), pustular rash (Moustou 2009), Stevens-Johnson syndrome, toxic epidermal necrolysis (Meiss 2007)

Gastrointestinal: Cholestasis, malignant neoplasm of colon or rectum

Genitourinary: Malignant neoplasm of breast, malignant neoplasm of cervix

Hematologic & oncologic: Agranulocytosis, hepatosplenic T-cell lymphomas (mainly adolescent or young adult males), Hodgkin lymphoma, immune thrombocytopenia, leukemia, malignant neoplasm, non-Hodgkin lymphoma, thrombotic thrombocytopenic purpura

Hepatic: Acute hepatic failure (Björnsson 2022), autoimmune hepatitis (Ghabril 2013), cholestatic hepatitis (including vanishing bile duct syndrome) (Björnsson 2022) hepatotoxicity (idiosyncratic) (Björnsson 2022), increased serum transaminases (Shah 2020), jaundice

Hypersensitivity: Anaphylactic shock

Infection: Aspergillosis, atypical mycobacterial infection, blastomycosis, fungal infection, listeriosis, parasitic infection, reactivation of HBV (Loomba 2017)

Nervous system: Cerebrovascular accident, demyelinating disease (peripheral; including chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, multifocal motor neuropathy) (Kemanetzoglou 2017), demyelinating disease of the central nervous system (including multiple sclerosis) (Kemanetzoglou 2017), neuropathy, transverse myelitis (Kunchok 2020)

Neuromuscular & skeletal: Lupus-like syndrome (Choi 2021)

Ophthalmic: Optic neuritis (Dermawan 2020), temporary vision loss

Respiratory: Bacterial pneumonia (legionnaires’ disease), bronchospasm, dyspnea (Lichtenstein 2015), interstitial lung disease (including interstitial pneumonitis, pulmonary fibrosis), laryngeal edema, pharyngeal edema

Contraindications

Previous severe hypersensitivity (eg, anaphylaxis, hypotension, serum sickness) to infliximab, murine proteins, or any component of the formulation; doses >5 mg/kg in patients with moderate or severe heart failure (NYHA class III/IV).

Canadian labeling: Additional contraindications (not in US labeling): Severe infections (eg, sepsis, abscesses, tuberculosis, and opportunistic infections); use in patients with moderate or severe heart failure (NYHA class III/IV).

Warnings/Precautions

Concerns related to adverse effects:

• Antibody formation: Formation of neutralizing anti-drug antibodies may occur with biologic tumor necrosis factor (TNF) inhibitors and may be associated with loss of efficacy (AAD-NPF [Menter 2019]).

• Cardiovascular/cerebrovascular reactions during and following infusion: Cerebrovascular accidents, MI (some fatal), hypotension, hypertension, and arrhythmias have been reported within 24 hours of infusion. Transient vision loss has also been reported during or within 2 hours of infusion. Discontinue therapy if serious reaction occurs.

• Hematologic disorders: Hematologic toxicities (eg, leukopenia, neutropenia, thrombocytopenia, pancytopenia) have been reported (may be fatal).

Disease-related concerns:

• Active infection: Do not initiate infliximab therapy in patients with an active infection, including clinically important localized infection.

• HIV: Use with caution in HIV-positive patients; TNF-α inhibitors may be appropriate in patients receiving highly active antiretroviral therapy, provided they have normal CD4 counts, no viral load, and no recent opportunistic infections (AAD-NPF [Menter 2019]).

• Seizure disorders: Use with caution in patients with a history of seizures; discontinue if significant CNS adverse reactions develop.

• Solid organ transplant: Consider holding infliximab prior to living donor solid organ transplant (eg, hold IV infliximab for at least 4 weeks; hold SUBQ infliximab for 1 week) (Szczepanik 2022).

Special populations:

• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).

Dosage form specific issues:

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there are no data available concerning secondary transmission of live vaccines in patients receiving therapy. A fatal outcome has been reported in an infant who received a live vaccine (BCG) after in utero exposure to infliximab. It is recommended to wait ≥6 months following birth before administering any live vaccine to infants exposed to infliximab in utero (Remsima [Canadian product] recommends waiting until 12 months of age).

Product Availability

Ixifi (infliximab-qbtx): FDA approved December 2017; anticipated availability is currently undetermined.

Zymfentra: FDA approved October 2023; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Zymfentra is indicated for subcutaneous administration for the maintenance treatment of moderately to severely active ulcerative colitis or Crohn disease following initial therapy with intravenous infliximab. Consult the prescribing information for additional information.

Dosage Forms Considerations

Remicade contains sucrose 500 mg per vial.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous [preservative free]:

Avsola: infliximab-axxq 100 mg (1 ea) [contains polysorbate 80]

Inflectra: infliximab-dyyb 100 mg (1 ea) [contains polysorbate 80]

Remicade: 100 mg (1 ea) [contains polysorbate 80]

Renflexis: infliximab-abda 100 mg (1 ea) [contains polysorbate 80]

Generic: 100 mg (1 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (reconstituted) (Avsola Intravenous)

100 mg (per each): $600.00

Solution (reconstituted) (Inflectra Intravenous)

100 mg (per each): $1,135.54

Solution (reconstituted) (inFLIXimab Intravenous)

100 mg (per each): $570.00

Solution (reconstituted) (Remicade Intravenous)

100 mg (per each): $1,401.38

Solution (reconstituted) (Renflexis Intravenous)

100 mg (per each): $904.07

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Auto-injector Kit, Subcutaneous:

Remsima SC: 120 mg/mL (1 ea) [contains polysorbate 80]

Solution Reconstituted, Intravenous:

Avsola: 100 mg (1 ea) [contains polysorbate 80]

Inflectra: 100 mg (1 ea) [contains polysorbate 80]

Remicade: 100 mg (1 ea) [contains polysorbate 80]

Renflexis: 100 mg (1 ea) [contains polysorbate 80]

Administration: Adult

IV: The infusion should begin within 3 hours of reconstitution and dilution. Infuse over at least 2 hours, although use of shortened infusion duration (eg, 1 hour) has been utilized in patients previously tolerating at least four 2-hour infusions (Ref); also refer to institution-specific protocols. Do not infuse with other agents; use in-line low protein binding filter (≤1.2 micron). Temporarily discontinue or decrease infusion rate with infusion-related reactions. Antihistamines (H1-antagonist +/- H2-antagonist), acetaminophen and/or corticosteroids may be used to manage reactions. Infusion may be reinitiated at a lower rate upon resolution of mild to moderate symptoms. Re-treatment in psoriasis patients should be resumed as a scheduled maintenance regimen without any induction doses; use of an induction regimen should be used cautiously for re-treatment of all other patients (Ref).

Recommendations for treatment and prophylaxis of infusion reactions: (Note: Limited to adult patients and dosages used in Crohn disease; prospective data for other populations [pediatrics, other indications/dosing] are not available).

A protocol for the treatment of infusion reactions, as well as prophylactic therapy for repeat infusions, has been published (Ref).

Treatment of infusion reactions: Medications for the treatment of hypersensitivity reactions should be available for immediate use. For mild reactions, the rate of infusion should be decreased to 10 mL/hour. Initiate a normal saline infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment (eg, acetaminophen and diphenhydramine); monitor vital signs every 10 minutes until normal. After 20 minutes, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase to 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For moderate reactions, the infusion should be stopped or slowed. Initiate a normal saline infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment. Monitor vital signs every 5 minutes until normal. After 20 minutes, the infusion may be reinstituted at 10 mL/hour; then increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For severe reactions, the infusion should be stopped with administration of appropriate symptomatic treatment (eg, hydrocortisone/methylprednisolone, diphenhydramine and epinephrine) and frequent monitoring of vitals (consult institutional policies, if available). Re-treatment after a severe reaction should only be done if the benefits outweigh the risks and with appropriate prophylaxis. Delayed infusion reactions typically occur 1 to 7 days after an infusion. Treatment should consist of appropriate symptomatic treatment (eg, acetaminophen, antihistamine, methylprednisolone).

Prophylaxis of infusion reactions: Premedication with acetaminophen and diphenhydramine 90 minutes prior to infusion may be considered in all patients with prior infusion reactions, and in patients with severe reactions corticosteroid administration is recommended. Steroid dosing may be oral (prednisone 50 mg orally every 12 hours for 3 doses prior to infusion) or intravenous (a single dose of hydrocortisone 100 mg or methylprednisolone 20 to 40 mg administered 20 minutes prior to the infusion). On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc). A maximum rate of 125 mL/hour is recommended in patients who experienced prior mild to moderate reactions and 100 mL/hour is recommended in patients who experienced prior severe reactions. In patients with cutaneous flushing, aspirin may be considered (Ref). For delayed infusion reactions, premedicate with acetaminophen and diphenhydramine 90 minutes prior to infusion. On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased to infuse over 3 hours. Postinfusion therapy with acetaminophen for 3 days and an antihistamine for 7 days is recommended.

SUBQ: Remsima (Canadian product): Allow syringe to warm to room temperature prior to use (30 minutes); do not use heat sources to warm (eg, hot water, microwave). Inject into outer area of upper arms (caregiver only), abdomen (do not use within 5 cm of belly button), or front of thighs. Rotate injection site with each dose; administer at least 3 cm away from previous injection site. Do not administer into bruised, damaged, scarred, or tender skin. Do not use damaged syringe; do not reuse or shake syringe. Administer first dose under supervision of health care provider. After proper training, patients may self-inject, or the patient's caregiver may administer.

Administration: Pediatric

Parenteral: The infusion should begin within 3 hours (Avsola, Inflectra, Remicade) or 4 hours (Renflexis) of preparation. Administer by IV infusion through an in-line, sterile, nonpyrogenic, low-protein-binding filter with pore size of ≤1.2 micrometers; do not infuse in the same IV line as other agents. The manufacturer recommends to infuse over at least 2 hours; however, rapid infusion times of 1 hour have been described in patients with ulcerative colitis on a stable maintenance dose (Ref); a rate titration schedule may be used to prevent acute infusion reactions. Temporarily discontinue or decrease infusion rate if infusion-related reactions occur. Antihistamines (H1-antagonist ± H2-antagonist), acetaminophen, and/or corticosteroids may be used to manage infusion reactions. Infusion may be reinitiated at a lower rate upon resolution of mild to moderate symptoms.

Guidelines for the treatment and prophylaxis of infusion reactions: There are no pediatric-specific guidelines available. In adults, the following protocol for the treatment of infusion reactions, as well as prophylactic therapy for repeat infusions, has been published (Ref).

Treatment of infusion reactions: Adults: Medications for the treatment of hypersensitivity reactions should be available for immediate use. For mild reactions, the rate of infusion should be decreased to 10 mL/hour. Initiate an NS infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment (eg, acetaminophen, diphenhydramine); monitor vital signs every 10 minutes until normal. After 20 minutes, the infliximab infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase to 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For moderate reactions, the infusion should be stopped or slowed. Initiate an NS infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment. Monitor vital signs every 5 minutes until normal. After 20 minutes, the infliximab infusion may be reinstituted at 10 mL/hour; then increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For severe reactions, the infusion should be stopped with administration of appropriate symptomatic treatment (eg, hydrocortisone/methylprednisolone, diphenhydramine, epinephrine) and frequent monitoring of vitals. Retreatment after a severe reaction should only be done if the benefits outweigh the risks and with appropriate prophylaxis. Delayed infusion reactions typically occur 1 to 7 days after an infusion. Treatment should consist of appropriate symptomatic treatment (eg, acetaminophen, antihistamine, methylprednisolone).

Prophylaxis of infusion reactions: Adults: Premedication with acetaminophen and diphenhydramine 90 minutes prior to infusion may be considered in all patients with prior infusion reactions, and in patients with severe reactions, corticosteroid administration is recommended. Steroid dosing may be oral (prednisone 50 mg orally every 12 hours for 3 doses prior to infusion) or intravenous (a single dose of hydrocortisone 100 mg or methylprednisolone 20 to 40 mg administered 20 minutes prior to the infusion). Upon initiation of the infusion, begin with a test dose at 10 mL/hour of infliximab for 15 minutes. Thereafter, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc). A maximum rate of 125 mL/hour is recommended in patients who experienced prior mild-moderate reactions and 100 mL/hour is recommended in patients who experienced prior severe reactions. In patients with cutaneous flushing, aspirin may be considered (Ref). For delayed infusion reactions, premedicate with acetaminophen and diphenhydramine 90 minutes prior to infusion. Upon initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased to infuse over 3 hours. Postinfusion therapy with acetaminophen for 3 days and an antihistamine for 7 days is recommended. Note: In a trial of pediatric patients, premedication with acetaminophen (20 mg/kg; maximum single dose: 1,000 mg) and cetirizine (0.3 mg/kg if <5 years, 10 mg if ≥5 years) did not significantly impact incidence of infusion-related reactions; patients should be monitored closely (Ref).

Use: Labeled Indications

Ankylosing spondylitis: Treatment of adults with active ankylosing spondylitis (to reduce signs/symptoms).

Crohn disease: Treatment of adults and pediatric patients ≥6 years of age with moderately to severely active Crohn disease who have had inadequate responses to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission) or to reduce the number of draining enterocutaneous and rectovaginal fistulas and maintain fistula closure in adults.

Plaque psoriasis: Treatment of adults with chronic, severe (extensive and/or disabling) plaque psoriasis as an alternative to other systemic therapy.

Psoriatic arthritis: Treatment of adults with psoriatic arthritis (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function).

Rheumatoid arthritis: Treatment of adults with moderately to severely active rheumatoid arthritis (with methotrexate) (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function).

Ulcerative colitis: Treatment of adults and pediatric patients ≥6 years of age with moderately to severely active ulcerative colitis with inadequate response to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission) or to induce/maintain mucosal healing and eliminate corticosteroid use in adults.

Note: Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), and Renflexis (infliximab-abda) are approved as biosimilars to Remicade (infliximab). In Canada, Avsola, Inflectra, and Renflexis are also approved as biosimilars to Remicade (infliximab).

Use: Off-Label: Adult

Colitis, immune checkpoint inhibitor-induced; COVID-19, hospitalized patients; Pustular psoriasis; Pyoderma gangrenosum; Sarcoidosis, refractory

Medication Safety Issues
Sound-alike/look-alike issues:

InFLIXimab may be confused with idaruCIZUmab, riTUXimab

Remicade may be confused with Renacidin, Rituxan

High alert medication:

This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Abatacept: Anti-TNF Agents may enhance the immunosuppressive effect of Abatacept. Risk X: Avoid combination

Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. Risk X: Avoid combination

Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. Risk X: Avoid combination

Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor therapy

AzaTHIOprine: InFLIXimab may enhance the adverse/toxic effect of AzaTHIOprine. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. InFLIXimab may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Risk C: Monitor therapy

Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. Risk X: Avoid combination

BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. Risk X: Avoid combination

Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined. Risk D: Consider therapy modification

Biologic Anti-Psoriasis Agents: InFLIXimab may enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Risk X: Avoid combination

Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Risk X: Avoid combination

Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. Risk C: Monitor therapy

Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. Risk X: Avoid combination

Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. Risk X: Avoid combination

Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). Risk X: Avoid combination

Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. Risk X: Avoid combination

Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider therapy modification

COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters). Risk D: Consider therapy modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor therapy

COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider therapy modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). Risk C: Monitor therapy

COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). Risk C: Monitor therapy

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). Risk X: Avoid combination

Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections. Risk D: Consider therapy modification

Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy

Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. Risk C: Monitor therapy

Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored. Risk D: Consider therapy modification

Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents. Risk D: Consider therapy modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Risk X: Avoid combination

Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid combination

Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. Risk X: Avoid combination

Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. Risk C: Monitor therapy

Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. Risk C: Monitor therapy

Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. Risk X: Avoid combination

Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. Risk C: Monitor therapy

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Risk X: Avoid combination

Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification

Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider therapy modification

Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. Risk X: Avoid combination

Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. Risk X: Avoid combination

Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy

Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). Risk X: Avoid combination

Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk C: Monitor therapy

Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). Risk X: Avoid combination

Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid combination

Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. Risk X: Avoid combination

Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. Risk C: Monitor therapy

Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials. Risk X: Avoid combination

Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. Risk X: Avoid combination

Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. Risk C: Monitor therapy

Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. Risk X: Avoid combination

Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete. Risk D: Consider therapy modification

Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. Risk X: Avoid combination

Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. Risk X: Avoid combination

Reproductive Considerations

Infliximab may be used in patients with rheumatic and musculoskeletal diseases who are planning to become pregnant. Conception should be planned during a period of quiescent/low disease activity (ACR [Sammaritano 2020]).

Patients with psoriasis planning to become pregnant may continue treatment with infliximab. Patients with well-controlled psoriasis who wish to avoid fetal exposure can consider discontinuing infliximab 50 days prior to attempting to become pregnant (Rademaker 2018).

Biologics, such as infliximab, may be continued in patients with inflammatory bowel disease planning to become pregnant (Mahadevan 2019). Treatment algorithms are available for use of biologics in patients with Crohn disease who are planning to become pregnant (Weizman 2019). Serum levels should be optimized prior to conception (Mahadevan 2019).

Infliximab is recommended for use in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).

The American Academy of Dermatology considers tumor necrosis factor alpha (TNFα)-blocking agents for the treatment of psoriasis to be compatible for use in patients planning to father a child (AAD-NPF [Menter 2019]).

Pregnancy Considerations

Infliximab crosses the placenta.

Infliximab is a chimeric monoclonal antibody (IgG1). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).

In some cases, cord blood and newborn concentrations of infliximab may be greater than maternal serum at delivery (Ghalandari 2022; Julsgaard 2016; Mahadevan 2013). This was also observed with an infliximab biosimilar (infliximab-dyyb) (Kawamoto 2022). There is an inverse correlation between the duration since last maternal dose and cord blood concentrations at delivery (Ghalandari 2022; Julsgaard 2016; Mahadevan 2013). The mean time to infliximab clearance was 7.3 months (range: 6.2 to 8.3 months) in a study in 44 infants exposed in utero (last maternal dose at 30 weeks' gestation [mean; range 8 to 37 weeks]). Infliximab serum concentrations remained detectable in one infant until 12 months of age (Julsgaard 2016). Discontinuing infliximab prior to 20 weeks' gestation resulted in undetectable or low cord blood concentrations in one study of 14 patients (Ghalandari 2022).

Outcome data following maternal use of infliximab are available (Geldhof 2020; MacIsaac 2022; Wang 2022). Based on available data, product labeling notes an increased risk of major birth defects has not been observed following infliximab exposure during pregnancy. Data related to this class of medications are emerging, but based on available data, tumor necrosis factor alpha (TNFα)-blocking agents are considered to have low to moderate risk when used in pregnancy (ACOG 2019).

A paper describes agranulocytosis requiring treatment with granulocyte colony stimulating factor in four infants (3 of which were triplets) exposed to infliximab in utero. In the singleton pregnancy, infliximab was present in the newborn serum 13 weeks after the last maternal pregnancy dose, but concentrations were not measurable in the mother. Infliximab serum concentrations were not evaluated in the triplets (Guiddir 2014).

Adverse outcomes, including fatalities, have been reported in infants who received the live BCG vaccine after in utero exposure to infliximab (Goulden 2022). The risk of immunosuppression may be increased following third trimester maternal use of TNFα-blocking agents; the fetus, neonate/infant should be considered immunosuppressed following in utero exposure (AAD-NPF [Menter 2019]). Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, >27 weeks' gestation) (Mahadevan 2019).

Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of infliximab may be altered. Clearance may be decreased as pregnancy progresses leading to an increase in maternal plasma concentrations; therapeutic drug monitoring may be required in some patients (Wiersma 2022).

Recommendations for use of infliximab during pregnancy vary by indication and guideline (Romanowska-Próchnicka 2021). Use of immune-modulating therapies in pregnancy should be individualized to optimize maternal disease and pregnancy outcomes (ACOG 2019).

The American Academy of Dermatology (AAD) considers TNFα-blocking agents for the treatment of psoriasis to be compatible with pregnancy (AAD-NPF [Menter 2019]).

Inflammatory bowel disease is associated with adverse pregnancy outcomes, including an increased risk of miscarriage, premature delivery, delivery of a low-birth-weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes (Mahadevan 2019). When treatment for inflammatory bowel disease is needed in pregnant patients, the American Gastroenterological Association notes appropriate biologic therapy can be continued without interruption. Weight based dosing can be done using prepregnancy body weight and adjusted as needed based on disease activity and serum concentrations. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels, which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For infliximab, the final injection can be given 6 to 10 weeks prior to the estimated date of delivery, then restarted 48 hours postpartum (Mahadevan 2019).

According to the American College of Rheumatology, infliximab may be continued during the first and second trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases. Use should be discontinued during the third trimester in patients with well-controlled disease. Newborn exposure should be considered if treatment cannot be discontinued due to active disease (ACR [Sammaritano 2020]).

Infliximab is also used off label for the treatment of COVID-19. The risk of severe morbidity and mortality from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID-19. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO). Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2023).

In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients; however, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process. Pregnancy is a risk factor for severe COVID-19. The use of infliximab in hospitalized pregnant patients is recommended if indicated when other agents are not available or feasible to use; also consider GA of the fetus (NIH 2023). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.

Data collection to monitor maternal and infant outcomes following exposure to COVID-19 during pregnancy is ongoing. Health care providers are encouraged to enroll patients exposed to COVID-19 during pregnancy in the Organization of Teratology Information Specialists pregnancy registry (1-877-311-8972; https://mothertobaby.org/join-study/).

Breastfeeding Considerations

Infliximab is present in breast milk.

Infliximab is a chimeric monoclonal antibody (IgG1). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).

The potential transfer of infliximab into breast milk has been evaluated in multiple studies. Data are available from three postpartum women who were administered infliximab 5 mg/kg 1 to 24 weeks after delivery. Infliximab was detected within 12 hours and the highest milk concentrations were seen 2 to 3 days after the maternal dose (Ben-Horin 2011). In a study of 29 women, 19 had detectable breast milk concentrations with maximum concentrations occurring between 24 and 48 hours after the infusion (Matro 2018). A smaller study of three postpartum patients demonstrated breast milk concentrations can be variable within a single woman over one dosing period (Grosen 2014). Infliximab could not be detected in breast milk in some studies (Kane 2009; Stengel 2008; Vasiliauskas 2006).

In one case report, subtherapeutic infliximab concentrations were observed in a breastfed infant only exposed during breastfeeding (Fritzsche 2012). Adverse events were not observed in breastfed infants in the studies which demonstrated detectable milk concentrations and evaluated this outcome (Grosen 2014; Matro 2018).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. However, tumor necrosis factor alpha (TNFα)-blocking agents, including infliximab, are considered compatible with breastfeeding (AAD-NPF [Menter 2019]; ACOG 776 2019; ACR [Sammaritano 2020]; Mahadevan 2019).

Breast milk has not been found to be a source of COVID-19 infection and maternal infection is not a contraindication to breastfeeding. The decision to breastfeed during treatment for COVID-19 should be evaluated as part of a shared decision-making process. Infliximab can be used in breastfeeding patients if needed for the management of COVID-19; however, lactating patients with COVID-19 infection can transmit the virus through respiratory droplets and all precautions should be taken to avoid spreading the virus to the infant (eg, hand hygiene, mask wearing); alternatively, breast milk can be expressed and fed to the infant by someone without confirmed or suspected COVID-19 (ACOG 2023; NIH 2023).

Information related to COVID-19 and breastfeeding is available from the World Health Organization (https://www.who.int/news/item/28-04-2020-new-faqs-address-healthcare-workers-questions-on-breastfeeding-and-covid-19).

Monitoring Parameters

CBC with differential (baseline); complete metabolic panel (baseline); tuberculosis (TB) screening prior to initiating and during therapy (chest Xray if TB positive); hepatitis b virus (HBV)/hepatitis C virus screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); HIV screening (baseline) (AAD-NPF [Menter 2019]); LFTs (baseline and periodically during therapy; more frequently in patients with elevated LFTs; discontinue if >5 times ULN); signs/symptoms of infection, heart failure, hypersensitivity reaction, lupus-like syndrome, malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss); signs and symptoms suggestive of blood dyscrasias (eg, persistent fevers). During infusion, if reaction is noted, monitor vital signs every 2 to 10 minutes, depending on reaction severity, until normal. If a serious reaction occurs (eg, cardiovascular or cerebrovascular reaction), discontinue the infusion. Monitor improvement of symptoms and physical function assessments.

Psoriasis patients with history of phototherapy should be monitored for nonmelanoma skin cancer. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk for skin cancer. Women should be screened periodically for cervical cancer.

The American Gastroenterological Association suggests reactive therapeutic drug monitoring to guide treatment changes in adult patients treated with infliximab for active inflammatory bowel disease (Feuerstein 2017).

Reference Range

Adults:

Inflammatory bowel disease (IBD):

Reactive therapeutic drug monitoring has been suggested to guide treatment changes in adults with active IBD.

Timing of serum sample: Draw trough <24 hours prior to next scheduled dose

Therapeutic reference range: ≥5 mcg/mL (Feuerstein 2017)

Mechanism of Action

Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), thereby interfering with endogenous TNFα activity. Elevated TNFα levels have been found in involved tissues/fluids of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn disease and ulcerative colitis. Biological activities of TNFα include the induction of proinflammatory cytokines (interleukins), enhancement of leukocyte migration, activation of neutrophils and eosinophils, and the induction of acute phase reactants and tissue degrading enzymes. Animal models have shown TNFα expression causes polyarthritis, and infliximab can prevent disease as well as allow diseased joints to heal.

Pharmacokinetics (Adult Data Unless Noted)

Note: Pharmacokinetic data in pediatric patients (6 to 17 years) reported to be similar to adult values.

Onset of action: Crohn disease: 1 to 2 weeks; Rheumatoid arthritis: 3 to 7 days; Psoriasis: 8 to 10 weeks (AAD-NPF [Menter 2019]).

Duration of action: Crohn disease: 8 to 48 weeks; Rheumatoid arthritis: 6 to 12 weeks.

Distribution: Within the vascular compartment; Vd: 3 to 6 L (Klotz 2007); Remsima (Canadian product): Terminal phase: 7.3 to 8.8 L.

Half-life elimination: 7 to 12 days (Klotz 2007); Remsima (Canadian product): Terminal: 11.3 to 13.7 days.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Ixifi | Remicade | Remsima;
  • (AR) Argentina: Ixifi | Remicade | Remsima;
  • (AT) Austria: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (AU) Australia: Inflectra | Remicade | Remsima | Renflexis;
  • (BD) Bangladesh: Remicade;
  • (BE) Belgium: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (BG) Bulgaria: Inflectra | Remicade | Remsima | Zessly;
  • (BR) Brazil: Avsola | Bio manguinhos infliximabe | Remicade | Remsima | Renflexis | Xilfya;
  • (CH) Switzerland: Inflectra | Remicade | Remicade lyophilisat | Remsima | Veblocema;
  • (CL) Chile: Remicade | Remsima;
  • (CN) China: Remicade;
  • (CO) Colombia: Remicade | Remsima;
  • (CZ) Czech Republic: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (DE) Germany: Flixabi | Inflectra | Remicade | Remsima | Remsima sc | Zessly;
  • (DO) Dominican Republic: Remicade;
  • (EC) Ecuador: Remicade;
  • (EE) Estonia: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (EG) Egypt: Remicade;
  • (ES) Spain: Flixabi | Inflectra | Remsima | Zessly;
  • (FI) Finland: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (FR) France: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (GB) United Kingdom: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (GR) Greece: Inflectra | Remicade | Remsima | Zessly;
  • (HK) Hong Kong: Remicade | Remsima;
  • (HR) Croatia: Inflectra | Remicade | Remsima | Zessly;
  • (HU) Hungary: Inflectra | Remicade | Remsima | Zessly;
  • (IE) Ireland: Flixabi | Inflectra | Remicade | Remsima;
  • (IL) Israel: Remicade;
  • (IN) India: Infimab;
  • (IT) Italy: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (JO) Jordan: Remsima;
  • (JP) Japan: Remicade;
  • (KE) Kenya: Remicade;
  • (KR) Korea, Republic of: Remaloce | Remicade | Remsima | Remsima sc | Renflexis;
  • (KW) Kuwait: Remicade | Remsima;
  • (LB) Lebanon: Ixifi | Remicade | Remsima;
  • (LT) Lithuania: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (LU) Luxembourg: Remsima;
  • (LV) Latvia: Remsima | Zessly;
  • (MA) Morocco: Remicade | Remsima;
  • (MX) Mexico: Ixifi | Remicade | Remsima;
  • (MY) Malaysia: Remicade | Remsima;
  • (NL) Netherlands: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (NO) Norway: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (NZ) New Zealand: Remicade;
  • (PE) Peru: Flixceli | Remicade;
  • (PH) Philippines: Remicade;
  • (PK) Pakistan: Remicade | Remsima;
  • (PL) Poland: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (PR) Puerto Rico: Remicade;
  • (PT) Portugal: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (PY) Paraguay: Remsima;
  • (QA) Qatar: Ixifi | Remicade | Remsima | Renflexis;
  • (RO) Romania: Inflectra | Remicade | Remsima | Zessly;
  • (RU) Russian Federation: Flammegis | Remicade | Remicaid;
  • (SA) Saudi Arabia: Ixifi | Remicade | Remsima;
  • (SE) Sweden: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (SG) Singapore: Remicade | Remsima;
  • (SI) Slovenia: Flixabi | Inflectra | Remicade | Remsima | Zessly;
  • (SK) Slovakia: Inflectra | Remicade | Remsima | Zessly;
  • (TH) Thailand: Remicade | Remsima;
  • (TN) Tunisia: Remicade | Remsima;
  • (TR) Turkey: Ixifi | Remicade | Remsima;
  • (TW) Taiwan: Remicade | Remsima;
  • (UA) Ukraine: Flammegis | Remicade | Remicaide;
  • (UY) Uruguay: Remicade;
  • (VE) Venezuela, Bolivarian Republic of: Remicade;
  • (ZA) South Africa: Remiflix | Remsima | Revellex;
  • (ZM) Zambia: Remicade
  1. Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. Cardiol Rev. 2006;14(1):50-52. doi:10.1097/01.crd.0000178320.51474.ac [PubMed 16371767]
  2. Aby ES, Lake JR, Vaughn BP. The impact of biologics for the management of inflammatory bowel disease on liver enzymes. Clin Liver Dis (Hoboken). 2020;16(5):212-217. doi:10.1002/cld.1005 [PubMed 33318791]
  3. Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229-2237. doi:10.3899/jrheum.150057 [PubMed 26472414]
  4. Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  5. Almeida DE, Costa E, Neves JS, Cerqueira M, Ribeiro AR. Cutaneous vasculitis and granulomatous hepatitis as paradoxical adverse events of Infliximab. Acta Reumatol Port. 2020;45(2):156-157. [PubMed 32895360]
  6. Almuntashri F, Binyaseen K, Alkhotani A. Chronic inflammatory demyelinating polyneuropathy in patients with Crohn's disease on infliximab therapy. Cureus. 2021;13(10):e19041. doi:10.7759/cureus.19041 [PubMed 34858738]
  7. American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 776: immune modulating therapies in pregnancy and lactation. Obstet Gynecol. 2019;133(4):e287-e295. [PubMed 30913201]
  8. American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 4, 2023.
  9. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(RR-6):1-51 [PubMed 10881762]
  10. Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110 [PubMed 33956488]
  11. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010;55(2):333-338. doi:10.1161/HYPERTENSIONAHA.109.143982 [PubMed 20038753]
  12. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005;52(4):1227-1236. [PubMed 15818699]
  13. Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(6):998-1003. doi:10.1136/annrheumdis-2013-204531 [PubMed 24458537]
  14. Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68(5):648-653. doi:10.1136/ard.2007.085852 [PubMed 18467516]
  15. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1421-1426. doi:10.1136/ard.2004.033993 [PubMed 15829572]
  16. Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: a review. J Clin Transl Hepatol. 2018;6(4):402-409. doi:10.14218/JCTH.2018.00039 [PubMed 30637218]
  17. Avsola (infliximab-axxq) [prescribing information]. Thousand Oaks, CA: Amgen Inc; September 2021.
  18. Avsola (infliximab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; March 2020.
  19. Avsola (infliximab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; May 2022.
  20. Bae JM, Lee HH, Lee BI. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196-205. doi:10.1111/apt.14822 [PubMed 29869804]
  21. Baughman RP, Drent M, Kavuru M, et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795-802. doi:10.1164/rccm.200603-402OC [PubMed 16840744]
  22. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079. doi:10.1183/13993003.04079-2020 [PubMed 34140301]
  23. Becker M, Rose CD, and McIlvain-Simpson G. Niacin-Like Reaction to Infliximab Infusion in Systemic Juvenile Rheumatoid Arthritis. J Rheumatol. 2004;31(12):2529-2530. [PubMed 15570667]
  24. Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555-558. [PubMed 22115374]
  25. Björnsson ES, Gunnarsson BI, Gröndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13(3):602-608. doi:10.1016/j.cgh.2014.07.062 [PubMed 25131534]
  26. Björnsson HK, Gudbjornsson B, Björnsson ES. Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol. 2022;76(1):86-92. doi:10.1016/j.jhep.2021.08.024 [PubMed 34487751]
  27. Boggs JME, Ramsay B, Lynch M. Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy. Clin Exp Dermatol. 2021;46(3):580-582. doi:10.1111/ced.14500 [PubMed 33151572]
  28. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF Antibody Therapy In Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials. JAMA. 2006;295(19):2275-2285. [PubMed 16705109]
  29. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435 [PubMed 34172516]
  30. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505-509. [PubMed 16188920]
  31. Bryant KD, DeNunzio MJ, Ford MJ. Linear IgA dermatosis after infliximab infusion for ulcerative colitis. JAAD Case Rep. 2016;2(6):448-450. [PubMed 27981215]
  32. Buch MH, Bryer D, Lindsay S, et al. Shortening Infusion Times for Infliximab Administration. Rheumatology (Oxford). 2006;45(4):485-486. [PubMed 16352636]
  33. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833-838. [PubMed 18672254]
  34. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146(5):662-667. [PubMed 15870671]
  35. Burns JC, Roberts SC, Tremoulet AH, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021;5(12):852-861. doi:10.1016/S2352-4642(21)00270-4 [PubMed 34715057]
  36. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009;28(8):1001-1003. doi:10.1007/s10067-009-1179-y [PubMed 19370307]
  37. Carpenter PA and Sanders JE. Steroid-refractory graft-vs-host disease: past, present and future. Pediatr Transplant. 2003;7(suppl 3):19-31. [PubMed 12603689]
  38. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. [PubMed 6423951]
  39. Centers for Disease Control. Testing and Treatment of Latent Tuberculosis Infection. MMWR Recomm Rep. 2000;49(RR-6).
  40. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966. [PubMed 24935270]
  41. Checkley LA, Kristofek L, Kile S, Bolgar W. Incidence and management of infusion reactions to infliximab in an alternate care setting. Dig Dis Sci. 2019;64(3):855-862. doi:10.1007/s10620-018-5319-6 [PubMed 30311152]
  42. Chen HK, Shao SC, Weng MY, et al. Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-α Inhibitors. Clin Pharmacol Ther. 2021;110(6):1595-1603. doi:10.1002/cpt.2415 [PubMed 34496051]
  43. Cheng FK, Bridges EE, Betteridge JD. Drug-induced liver injury from initial dose of infliximab. Mil Med. 2015;180(6):e723-e724. doi:10.7205/MILMED-D-14-00485 [PubMed 26032391]
  44. Choi SJ, Ahn SM, Oh JS, et al. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. Therap Adv Gastroenterol. 2021;14:1756284821997794. doi:10.1177/1756284821997794 [PubMed 33747126]
  45. Chung ES, Packer M, Lo KH, et al. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-Alpha, in Patients with Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) Trial. Circulation. 2003;107(25):3133-3140. [PubMed 12796126]
  46. Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. Front Immunol. 2020;11:1920. doi:10.3389/fimmu.2020.01920 [PubMed 33013843]
  47. Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016 Jan 5;164(1):10-22. doi:10.7326/M15-0729 [PubMed 26641955]
  48. Cole LD, Osborne CM, Silveira LJ, et al. IVIG compared to IVIG plus infliximab in multisystem inflammatory syndrome in children. Pediatrics. Published online September 21, 2021. doi:10.1542/peds.2021-052702 [PubMed 34548377]
  49. Conti F, Atzeni F, Massaro L, et al. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. Rheumatology (Oxford). 2018;57(Suppl 7):vii11-vii22. doi:10.1093/rheumatology/key209 [PubMed 30289537]
  50. Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study [formula: see text]. J Cutan Med Surg. 2020;24(4):333-339. doi:10.1177/1203475420917387 [PubMed 32527153]
  51. Couriel D, Saliba R, Hicks K, et al. Tumor Necrosis Factor-Alpha Blockade for the Treatment of Acute GVHD. Blood. 2004;104(3):649-654. [PubMed 15069017]
  52. Crandall WV, Mackner LM. Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome and a Predictive Model. Aliment Pharmacol Ther. 2003;17(1):75-84. [PubMed 12492735]
  53. Crowson CS, Liao KP, Davis JM 3rd, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166(4):622-628.e1. doi:10.1016/j.ahj.2013.07.010 [PubMed 24093840]
  54. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(12):4226-4227. doi:10.1002/art.23050 [PubMed 18050253]
  55. Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: a systematic review. Pediatr Dermatol. 2021;38(5):1086-1093. doi:10.1111/pde.14712 [PubMed 34402108]
  56. Darrigade AS, Milpied B, Truchetet ME, et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. Acta Derm Venereol. 2017;97(6):731-734. doi: 0.2340/00015555-2636 [PubMed 28218339]
  57. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145(6):1464-1478. [PubMed 24267475]
  58. deBruyn JC, Jacobson K, El-Matary W, et al. Long-term outcomes of infliximab use for pediatric Crohn disease: a Canadian multicenter clinical practice experience. J Pediatr Gastroenterol Nutr. 2018;66(2):268-273. doi:10.1097/MPG.0000000000001672 [PubMed 28657923]
  59. de Carvalho JF, dos Santos MNP, de Oliveira JMV, Silva ANSL, de Araujo RPC, Cardozo JB. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion. Adv in Rheumatol. 2018;58(22):1-3. [PubMed 30657070]
  60. Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7(7):517-524. doi:10.1016/j.crohns.2012.08.007 [PubMed 22960136]
  61. Dermawan A, So K, Venugopal K, Picardo S. Infliximab-induced optic neuritis. BMJ Case Rep. 2020;13(12):e236041. doi:10.1136/bcr-2020-236041 [PubMed 33370961]
  62. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 2000;161:1376-1395. [PubMed 10764337]
  63. Dommasch E, Gelfand JM. Is There Truly a Risk of Lymphoma From Biologic Therapies? Dermatol Ther. 2009;22(5):418-430. [PubMed 19845719]
  64. Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91-107. [PubMed 25078637]
  65. Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34(3):253-260. doi:10.1111/pde.13081 [PubMed 28211161]
  66. Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol. 2000;164(12):6193-6198. doi:10.4049/jimmunol.164.12.6193 [PubMed 10843670]
  67. Eiswerth MJ, Heckroth MA, Ismail A, Gondim DD, Kaufman R. Infliximab-induced vanishing bile duct syndrome. Cureus. 2022;14(2):e21940. doi:10.7759/cureus.21940 [PubMed 35273881]
  68. Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.
  69. Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74(6):1153-1159. doi:10.1016/j.jaad.2016.01.018 [PubMed 26965410]
  70. Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am. 2014;43(3):543-563. doi:10.1016/j.gtc.2014.05.002 [PubMed 25110258]
  71. Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022 [PubMed 34051983]
  72. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006 [PubMed 31945371]
  73. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827-834. doi:10.1053/j.gastro.2017.07.032 [PubMed 28780013]
  74. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi:10.1002/acr.24596 [PubMed 34101387]
  75. Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015a;110(8):1186-116. doi:10.1038/ajg.2015.205 [PubMed 26195181]
  76. Fréling E, Peyrin-Biroulet L, Poreaux C, et al. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. Eur J Gastroenterol Hepatol. 2015b;27(10):1200-1208. doi:10.1097/MEG.0000000000000436 [PubMed 26181108]
  77. French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-α agents. Drug Saf. 2016;39(3):199-208. doi:10.1007/s40264-015-0366-9 [PubMed 26692395]
  78. Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718-719. [PubMed 22858514]
  79. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30(1):41-44. doi:10.1016/j.jemermed.2005.01.033 [PubMed 16434333]
  80. García Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol. 2007;26(5):811-813. doi:10.1007/s10067-006-0253-y [PubMed 16550301]
  81. Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf. 2020;43(2):147-161. doi:10.1007/s40264-019-00881-8 [PubMed 31677004]
  82. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558-564.e3. doi:10.1016/j.cgh.2012.12.025 [PubMed 23333219]
  83. Ghalandari N, Kemper E, Crijns IH, et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis. 2022;81(3):402-405. doi:10.1136/annrheumdis-2021-221036 [PubMed 34493490]
  84. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758-764. doi:10.1016/j.jhep.2009.04.020 [PubMed 19560226]
  85. Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. Clin Chest Med. 2019;40(4):721-739. doi:10.1016/j.ccm.2019.07.003 [PubMed 31731980]
  86. Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res (Hoboken). 2022;74(9):1399-1408. doi:10.1002/acr.24893 [PubMed 35718887]
  87. Goulden B, Chua N, Parker E, Giles I. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatology (Oxford). 2022;61(10):3902-3906. doi:10.1093/rheumatology/keac141 [PubMed 35258557]
  88. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331-2339. doi:10.1001/jama.2011.1692 [PubMed 22056398]
  89. Grosen A, Julsgaard M, Kelsen J, Christensen LA. Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2014;8(2):175-176. [PubMed 24090905]
  90. Guiddir T, Frémond ML, Triki TB, et al. Anti-TNF-α therapy may cause neonatal neutropenia. Pediatrics. 2014;134(4):e1189-e1193. [PubMed 25266439]
  91. Hammam N, Evans M, Morgan E, et al. Treatment of sarcoidosis in US rheumatology practices: data from the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry. Arthritis Care Res (Hoboken). 2022;74(3):371-376. doi:10.1002/acr.24496 [PubMed 33105057]
  92. Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis. 2010;16(12):2109-2116. doi:10.1002/ibd.21290 [PubMed 20848473]
  93. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167-2172 [PubMed 16981296]
  94. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39(5):481-492. doi:10.1111/j.1600-0560.2012.01894.x [PubMed 22515220]
  95. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. Arthritis Rheumatol. Published online February 3, 2022. doi:10.1002/art.42062 [PubMed 35118829]
  96. Hohlfeld R. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler. 1996;1(6):376-378. doi:10.1177/135245859600100619 [PubMed 9345421]
  97. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19-27. doi:10.1016/j.jaci.2015.10.023 [PubMed 26768759]
  98. Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNFα inhibitor exposure: a retrospective cohort study. J Neuroimmunol. 2021;356:577587. doi:10.1016/j.jneuroim.2021.577587 [PubMed 33945946]
  99. Inflectra (infliximab-dyyb) [prescribing information]. New York, NY: Pfizer; May 2023.
  100. Inflectra (infliximab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; July 2020.
  101. Infliximab injection [prescribing information]. Horsham, PA: Janssen Biotech Inc; October 2021.
  102. Infliximab. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; February 10, 2017. [PubMed 31643528]
  103. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
  104. Ixifi (infliximab-qbtx) [prescribing information]. New York, NY: Pfizer; December 2017.
  105. Ixifi (infliximab-qbtx) [prescribing information]. New York, NY: Pfizer; January 2020.
  106. Ixifi (infliximab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; December 2021.
  107. Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut. 2022;71(1):34-42. doi:10.1136/gutjnl-2020-322339 [PubMed 33384335]
  108. Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6(1):103. doi:10.1186/s40425-018-0412-0 [PubMed 30305177]
  109. Juhász K, Buzás K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. Expert Rev Clin Immunol. 2013;9(4):335-348. doi:10.1586/eci.13.14 [PubMed 23557269]
  110. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110-119. [PubMed 27063728]
  111. Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO. Pathological findings in central nervous system demyelination associated with infliximab. Mult Scler. 2020;26(9):1124-1129. doi:10.1177/1352458519894710 [PubMed 31845616]
  112. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009;43(7):613-616. [PubMed 19142167]
  113. Kantasiripitak W, Verstockt B, Alsoud D, et al. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. Br J Clin Pharmacol. 2021;87(10):3776-3789. doi:10.1111/bcp.14785 [PubMed 33604964]
  114. Kapila N, Gonzalez A, Rosado JM, et al. Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study. Therap Adv Gastroenterol. 2021;14:17562848211037094. doi:10.1177/17562848211037094 [PubMed 34707687]
  115. Kawamoto A, Fujii T, Mitani R, Suzuki Y, Yauchi T, Okamoto R. Serum levels of infliximab biosimilar in a child delivered from a mother treated for ulcerative colitis. Inflamm Bowel Dis. 2022;28(8):1298-1299. doi:10.1093/ibd/izac111 [PubMed 35700275]
  116. Kelly D, O'Connell O, Henry M. Adalimumab-induced lupus serositis. BMJ Case Rep. 2015;2015:bcr2014207323. doi:10.1136/bcr-2014-207323 [PubMed 25739794]
  117. Kelsall J, Rogers P, Galindo G, De Vera MA. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. J Rheumatol. 2012;39(8):1539-1545. doi:10.3899/jrheum.110956 [PubMed 22589260]
  118. Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17(4):36. doi:10.1007/s11910-017-0742-1 [PubMed 28337644]
  119. Kim HS, You HS, Cho HH, et al. Two cases of generalized pustular psoriasis: successful treatment with infliximab. Ann Dermatol. 2014;26(6):787-788. [PubMed 25473247]
  120. Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis. 2010;69(7):1342-1345. doi:10.1136/ard.2009.124180 [PubMed 20472597]
  121. Klotz U, Teml A, Schwab M. Clinical Pharmacokinetics and Use of Infliximab. Clin Pharmacokinet, 2007;45(8):645-660. [PubMed 17655372]
  122. Kok B, Lester ELW, Lee WM, et al. Acute liver failure from tumor necrosis factor-α antagonists: report of four cases and literature review. Dig Dis Sci. 2018;63(6):1654-1666. doi:10.1007/s10620-018-5023-6 [PubMed 29564668]
  123. Koller T, Galambosova M, Filakovska S, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol. 2017;23(22):4102-4111. doi:10.3748/wjg.v23.i22.4102 [PubMed 28652663]
  124. Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J Mol Sci. 2018;19(6):1739. doi:10.3390/ijms19061739 [PubMed 29895751]
  125. Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler. 2019;25(8):1079-1085. doi:10.1177/1352458519828601 [PubMed 30767720]
  126. Kunchok A, Aksamit AJ Jr, Davis JM 3rd, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937-946. doi:10.1001/jamaneurol.2020.1162 [PubMed 32421186]
  127. Kwon HJ, Cot TR, Cuffe MS, Kramer JM, Braun MM. Tumor necrosis factor antagonists and heart failure. Annals of Internal Medicine. 2003;138:807-811. Available at https://doi.org/10.7326/0003-4819-138-10-200305200-00004 [PubMed Kwon.1]
  128. Lahdenne P, Wikström AM, Aalto K, et al. Prevention of Acute Adverse Events Related to Infliximab Infusions in Pediatric Patients. Arthritis Care Res (Hoboken). 2010;62(6):785-790. [PubMed 20535789]
  129. Lane MA, McDonald JR, Zeringue AL, et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore). 2011;90(2):139-145. doi:10.1097/MD.0b013e318211106a [PubMed 21358439]
  130. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70(10):1719-1725. doi:10.1136/ard.2010.148783 [PubMed 21719446]
  131. Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15(5):1031-1048. doi:10.1007/s12072-021-10239-x [PubMed 34427860]
  132. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156(3):486-491. doi:10.1111/j.1365-2133.2007.07682.x [PubMed 17300238]
  133. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136-1145. doi:10.1136/ard.2008.091025 [PubMed 18753157]
  134. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481-517. doi:10.1038/ajg.2018.27 [PubMed 29610508]
  135. Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806-815. doi:10.1093/ecco-jcc/jjv096 [PubMed 26092578]
  136. Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70-80. doi:10.1177/2475530318810851 [PubMed 31093599]
  137. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-3412. doi:10.1002/art.21386 [PubMed 16255017]
  138. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37(9):1108-1110. [PubMed 12374238]
  139. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297-1309. doi:10.1053/j.gastro.2017.02.009 [PubMed 28219691]
  140. Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis. JAMA. 2012;308(9):898-908. [PubMed 22948700]
  141. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  142. MacIsaac MB, Julsgaard M, Flanagan E, et al. Anti-TNFα induction therapy for patients with active inflammatory bowel disease during pregnancy: a case series. Inflamm Bowel Dis. 2022;28(4):652-655. doi:10.1093/ibd/izab227 [PubMed 34536074]
  143. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7(1):55-63. doi:10.1586/eci.10.90 [PubMed 21162650]
  144. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Am J Obstet Gynecol. 2019;220(4):308-323. [PubMed 30948039]
  145. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-292. [PubMed 23200982]
  146. Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Pustular skin reaction to tumor necrosis factor alpha antagonists in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(11):E26-27. doi:10.1097/MIB.0000000000000600 [PubMed 26422518]
  147. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155(3):696-704. [PubMed 29857090]
  148. Mayer L, Young Y. Infusion Reactions and Their Management. Gastroenterol Clin North Am. 2006;35(4):857-866. [PubMed 17129817]
  149. McConnell J, Parvulescu-Codrea S, Behm B, et al. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. World J Gastrointest Pharmacol Ther. 2012;3(5):74-82. doi:10.4292/wjgpt.v3.i5.74 [PubMed 23515325]
  150. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. [PubMed 28356445]
  151. Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch WCh, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol. 2007;21(5):717-719. doi:10.1111/j.1468-3083.2006.02026.x [PubMed 17448012]
  152. Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists. Pulm Ther. 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x [PubMed 34143362]
  153. Melo FJ, Magina S. Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol. 2018;57(12):1521-1532. doi:10.1111/ijd.14072 [PubMed 30028008]
  154. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057 [PubMed 30772098]
  155. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74(6):1087-1093. doi:10.1136/annrheumdis-2013-204851 [PubMed 24685910]
  156. Miehsler W, Novacek G, Wenzl H, et al; Austrian Society of Gastroenterology and Hepatology. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4(3):221-256. doi:10.1016/j.crohns.2009.12.001 [PubMed 21122513]
  157. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862-2869. doi:10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w [PubMed 11762947]
  158. Montolio Chiva L, Martínez Ferrer À, Mateu Puchades A, Campos Fernández C, Narváez Garcia J, Alegre Sancho JJ. Psoriasis induced by biological therapy. Reumatol Clin (Engl Ed). 2021;17(8):437-439. doi:10.1016/j.reumae.2020.06.003 [PubMed 34625145]
  159. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486-504. doi:10.1016/j.jaad.2008.10.060 [PubMed 19628303]
  160. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-487. doi:10.1136/ard.2010.135871 [PubMed 21216812]
  161. Nassar-Sheikh Rashid A, Schonenberg-Meinema D, Berends SE, van den Berg JM, Mathôt RAA. Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis. Ther Drug Monit. 2022;44(2):301-307. doi:10.1097/FTD.0000000000000914 [PubMed 34292215]
  162. National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guideline. https://www.covid19treatmentguidelines.nih.gov/. Updated October 13, 2023. Accessed October 16, 2023.
  163. National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]). https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/. Updated February 24, 2022. Accessed March 7, 2022.
  164. Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75(2):341-347. doi:10.1136/annrheumdis-2013-204987 [PubMed 25609412]
  165. Neves JM, Cunha N, Lencastre A, Cabete J. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review. Int J Dermatol. 2019;58(11):e226-e228. doi:10.1111/ijd.14585 [PubMed 31290151]
  166. Nguyen GC, Loftus EV Jr, Hirano I, et al; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of Crohn's disease after surgical resection. Gastroenterology. 2017;152(1):271-275. doi:10.1053/j.gastro.2016.10.038 [PubMed 27840074]
  167. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412-420. doi:10.1002/art.20855 [PubMed 15692992]
  168. O'Halloran JA, Ko ER, Anstrom KJ, et al; ACTIV-1 IM Study Group Members. Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA. 2023;330(4):328-339. doi:10.1001/jama.2023.11043 [PubMed 37428480]
  169. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(1):1-6. doi:10.1097/01.MIB.0000436951.80898.6d [PubMed 24280879]
  170. Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(6):e32-e69. [PubMed 27400984]
  171. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. [PubMed 22235228]
  172. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.e3. doi:10.1053/j.gastro.2013.10.052 [PubMed 24512909]
  173. Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease. World J Gastroenterol. 2006;12(38):6235-6238. doi:10.3748/wjg.v12.i38.6235 [PubMed 17036404]
  174. Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-α Inhibitor Therapy: Expanding the Groups at Risk. Eur J Gastroenterol Hepatol. 2011;23(12):1150-1156. [PubMed 21941193]
  175. Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:956463. doi:10.1155/2014/956463 [PubMed 24707412]
  176. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-344. [PubMed 19626656]
  177. Pérez-De-Lis M, Retamozo S, Flores-Chávez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf. 2017;16(11):1255-1271. doi:10.1080/14740338.2017.1372421 [PubMed 28854831]
  178. Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017;5(3):600-609. doi:10.1016/j.jaip.2016.12.001 [PubMed 28110056]
  179. Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42(7):880-888. doi:10.1111/apt.13352 [PubMed 26235565]
  180. Raaschou P, Frisell T, Askling J; ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015;74(12):2137-2143. doi:10.1136/annrheumdis-2014-205745 [PubMed 25107559]
  181. Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018;59(2):86-100. [PubMed 28543445]
  182. Radovanović-Dinić B, Tešić-Rajković S, Zivkovic V, Grgov S. Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int. 2018;38(5):715-724. doi:10.1007/s00296-018-4021-5 [PubMed 29627896]
  183. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-251. doi:10.1097/MD.0b013e3181441a68 [PubMed 17632266]
  184. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188-193. doi:10.1016/j.autrev.2009.10.003 [PubMed 19854301]
  185. Refer to manufacturer's labeling.
  186. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98(8):1821-1826. [PubMed 12907338]
  187. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; March 2020.
  188. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; October 2021.
  189. Remicade (infliximab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; October 2022.
  190. Remsima SC (infliximab) [product monograph]. Toronto, Ontario, Canada: Celltrion Healthcare Canada Limited; March 2023.
  191. Renflexis (infliximab-abda) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; January 2023.
  192. Renflexis (infliximab) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2020.
  193. Ringold S, Weiss PF, Colbert RA, et al; Juvenile Idiopathic Arthritis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66(7):1063-1072. doi:10.1002/acr.22259 [PubMed 24339215]
  194. Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279-288. [PubMed 22609220]
  195. Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol. 2015;21(24):7584-7588. doi:10.3748/wjg.v21.i24.7584 [PubMed 26140007]
  196. Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19(42):7327-7340. doi:10.3748/wjg.v19.i42.7327 [PubMed 24259964]
  197. Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The role of TNF-α and anti-TNF-α agents during preconception, pregnancy, and breastfeeding. Int J Mol Sci. 2021;22(6):2922. doi:10.3390/ijms22062922 [PubMed 33805757]
  198. Rossi RE, Parisi I, Despott EJ, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol. 2014;20(46):17352-1739. doi:10.3748/wjg.v20.i46.17352 [PubMed 25516646]
  199. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152 [PubMed 30840605]
  200. Rubin RL. Drug-induced lupus. Toxicology. 2005;209(2):135-147. doi:10.1016/j.tox.2004.12.025 [PubMed 15767026]
  201. Rufo PA, Denson LA, Sylvester FA, et al. Health Supervision in the Management of Children and Adolescents With IBD: NASPGHAN Recommendations. J Pediatr Gastroenterol Nutr. 2012;55(1):93-108. [PubMed 22516861]
  202. Ruperto N, Lovell DJ, Cuttica R, et al. A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis. Arthritis Rheum. 2007;56(9):3096-3106. [PubMed 17763439]
  203. Ruperto N, Lovell DJ, Cuttica R, et al. Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718-722. [PubMed 20237125]
  204. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-2476. [PubMed 16339095]
  205. Ryan BM, Romberg M, Wolters F, Stockbrugger RW. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. Eur J Gastroenterol Hepatol. 2004;16(9):941-942. doi:10.1097/00042737-200409000-00022 [PubMed 15316423]
  206. Sakkat A, Cox G, Khalidi N, et al. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respir Res. 2022;23(1):54. doi:10.1186/s12931-022-01971-5 [PubMed 35264154]
  207. Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor necrosis factor α and regulatory T cells in oncoimmunology. Front Immunol. 2018;9:444. doi:10.3389/fimmu.2018.00444 [PubMed 29593717]
  208. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi:10.1002/art.41191 [PubMed 32090480]
  209. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889-894. doi:10.1136/ard.2005.043166 [PubMed 16439435]
  210. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440 [PubMed 34724392]
  211. Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31. doi:10.1186/s13601-015-0073-8 [PubMed 26339470]
  212. Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25(4):453-472. doi:10.1016/j.cytogfr.2014.07.016 [PubMed 25169849]
  213. Senilă S, Seicean A, Fechete O, Grad A, Ungureanu L. Infliximab-induced acne and acute localized exanthematous pustulosis: case report. Dermatol Ther. 2017;30(6). doi:10.1111/dth.12554 [PubMed 28976720]
  214. Shah P, Sundaram V, Björnsson E. Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review. Hepatol Commun. 2020;4(2):172-184. doi:10.1002/hep4.1465 [PubMed 32025603]
  215. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  216. Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(10):972-979. doi:10.1111/apt.13159 [PubMed 25756190]
  217. Shergy WJ, Isern RA, Cooley DA, et al. Open Label Study to Assess Infliximab Safety and Timing of Onset of Clinical Benefit among Patients With Rheumatoid Arthritis. J Rheumatol. 2002;29(4):667-677. [PubMed 11950005]
  218. Simard JF, Neovius M, Askling J; ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum. 2012;64(11):3502-3510. doi:10.1002/art.34582 [PubMed 22886739]
  219. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011(2):CD008794. doi:10.1002/14651858.CD008794.pub2 [PubMed 21328309]
  220. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(1):69-81.e3. doi:10.1016/j.cgh.2019.02.044 [PubMed 30876964]
  221. Smith N, Harms KL, Hines AC, et al. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. J Am Acad Dermatol. 2013;68(6):e187-e189. [PubMed 23680215]
  222. Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449-1455. doi:10.1002/art.39098 [PubMed 25776112]
  223. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644-649. [PubMed 21129756]
  224. Sridhar S, Maltz RM, Boyle B, Kim SC. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. Inflamm Bowel Dis. 2018;24(9):2086-2092. doi:10.1093/ibd/izy112 [PubMed 29718343]
  225. Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34(1):51-58. doi:10.1111/j.1365-2036.2011.04682.x [PubMed 21535447]
  226. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol. 2008;14(19):3085-3087. [PubMed 18494064]
  227. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98(1):104-111. doi:10.1111/j.1572-0241.2003.07161.x [PubMed 12526944]
  228. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914-1920. doi:10.1136/ard.2011.151043 [PubMed 21791449]
  229. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5. doi:10.1186/ar2904 [PubMed 20064207]
  230. Sugiura K, Endo K, Akasaka T, Akiyama M. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. J Eur Acad Dermatol Venereol. 2015;29(10):2054-2056. doi:10.1111/jdv.12590 [PubMed 24910924]
  231. Szczepanik A, Choi D, Brady B, et al. The use of non-transplant biologics in solid organ transplant recipients: a practical review for the frontline clinician. Clin Transplant. 2022;36(7):e14743. doi:10.1111/ctr.14743 [PubMed 35690919]
  232. Szymanska E, Dadalski M, Sieczkowska-Golub J, et al. Premedication does not influence the incidence of infliximab infusion reactions in pediatric patients with inflammatory bowel disease-a single center case-control study. J Clin Med. 2021;10(14):3177. doi:10.3390/jcm10143177 [PubMed 34300342]
  233. Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40(10):1749-1755 doi:10.3899/jrheum.130133 [PubMed 23950184]
  234. Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating events following initiation of anti-TNFα therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e992. doi:10.1212/NXI.0000000000000992 [PubMed 33863839]
  235. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145(6):1459-1463. [PubMed 24267474]
  236. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800 [PubMed 29405329]
  237. Torii H, Nakagawa H; Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38(4):321-334. [PubMed 21544940]
  238. Torres MJ, Chaves P, Doña I, et al. T-cell involvement in delayed-type hypersensitivity reactions to infliximab. J Allergy Clin Immunol. 2011;128(6):1365-1367.e1. doi:10.1016/j.jaci.2011.06.050 [PubMed 21839501]
  239. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731-1738. doi:10.1016/S0140-6736(13)62298-9 [PubMed 24572997]
  240. Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg. 2004;8(4):224-228. [PubMed 16091999]
  241. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018a;67(2):257-291. doi:10.1097/MPG.0000000000002035 [PubMed 30044357]
  242. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018b;67(2):292-310. doi:10.1097/MPG.0000000000002036 [PubMed 30044358]
  243. Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605-1612. doi:10.1136/ard.2010.143347 [PubMed 21623000]
  244. van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. Published online October 7, 2020. doi:10.1093/ecco-jcc/jjaa161 [PubMed 33026087]
  245. van Wassenaer EA, Meester VL, Kindermann A, Koot BGP, Benninga MA, de Meij TGJ. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study. Eur J Clin Pharmacol. 2019;75(10):1445-1450. doi:10.1007/s00228-019-02715-z [PubMed 31332475]
  246. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4(10):1255-1258. [PubMed 17045211]
  247. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125(1):32-39. doi:10.1016/s0016-5085(03)00701-7 [PubMed 12851868]
  248. Viguier M, Aubin F, Delaporte E, et al; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol. 2012;148(12):1423-1425. [PubMed 23247492]
  249. Visvanathan S, Wagner C, Marini JC, et al; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J. 2010;8:24. [PubMed 20822542]
  250. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A. 1998;95(24):14447-14452. doi:10.1073/pnas.95.24.14447 [PubMed 9826720]
  251. Waldron JL, Schworer SA, Kwan M. Hypersensitivity and immune-related adverse events in biologic therapy. Clin Rev Allergy Immunol. 2022;62(3):413-431. doi:10.1007/s12016-021-08879-w [PubMed 34319562]
  252. Wang H, Hu Y, Chen F, Shen M. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2022;22(1):854. doi:10.1186/s12884-022-05191-z [PubMed 36402978]
  253. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004;31(4):808-810. [PubMed 15088313]
  254. Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of Crohn's disease using RAND/UCLA appropriateness methodology. Inflamm Bowel Dis. 2019;25(2):328-335. [PubMed 30346529]
  255. Wiersma TK, Visschedijk MC, de Boer NK, et al. The effect of pregnancy and inflammatory bowel disease on the pharmacokinetics of drugs related to inflammatory bowel disease-a systematic literature review. Pharmaceutics. 2022;14(6):1241. doi:10.3390/pharmaceutics14061241 [PubMed 35745812]
  256. Winter DA, Joosse ME, de Wildt SN, Taminiau J, de Ridder L, Escher JC. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. J Pediatr Gastroenterol Nutr. 2020;70(6):763-776. doi:10.1097/MPG.0000000000002631 [PubMed 32443029]
  257. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628-634. doi:10.1002/art.21568 [PubMed 16447241]
  258. Worland T, Chin KL, van Langenberg D, Garg M, Nicoll A. Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study. Ann Gastroenterol. 2020;33(2):162-169. doi:10.20524/aog.2020.0453 [PubMed 32127737]
  259. Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis. 2013;19(13):2778-2786. doi:10.1097/01.MIB.0000435435.91988.b6 [PubMed 24185311]
  260. Youn Y, Kim J, Hong YM, Sohn S. Infliximab as the first retreatment in patients with Kawasaki Disease resistant to initial intravenous immunoglobulin. Pediatr Infect Dis J. 2016;35(4):457-459. [PubMed 26673981]
  261. Yun H, Xie F, Delzell E, Chen L, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis. 2015;74(6):1065-1071. doi:10.1136/annrheumdis-2013-204011 [PubMed 24608404]
  262. Zou F, Faleck D, Thomas A, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021;9(11):e003277. doi:10.1136/jitc-2021-003277 [PubMed 34789551]
Topic 8984 Version 401.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟